<DOC>
	<DOCNO>NCT00035451</DOCNO>
	<brief_summary>Atrial fibrillation ( abnormal rhythm upper chamber heart ) common supraventricular arrhythmia ( type abnormal heart rhythm ) antiarrhythmic therapy often prescribe . The primary goal therapy maintain sinus rhythm ( normal heart rhythm ) reduce occurrence episode atrial fibrillation . The double-blind , placebo-controlled phase study design evaluate efficacy safety oral azimilide compare placebo sotalol , antiarrhythmic drug , maintain sinus rhythm patient require cardioversion ( electric shock correct heart rhythm ) correct atrial fibrillation . Once phase study complete , second phase different study design conduct . The second phase open-label , follow-up phase first study . The follow-up phase continue evaluate long-term safety daily oral dose azimilide patient complete double-blind , placebo-controlled phase study .</brief_summary>
	<brief_title>Efficacy Safety Evaluation Azimilide Sotalol v Placebo Treatment Patients With Atrial Fibrillation .</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Azimilide</mesh_term>
	<mesh_term>Sotalol</mesh_term>
	<criteria>Inclusion criterion : Documented ( 12lead ECG ) history symptomatic atrial fibrillation occur 48 hour 6 month screen Require procedure cardioversion ( electric shock correct abnormal rhythm ) In investigator 's opinion , likely maintain sinus rhythm cardioversion . Be anticoagulated accord recommendation Study Group Atrial Fibrillation European Society Cardiology guideline . Exclusion criterion : Previously unsuccessful electrical cardioversions Failed respond Class III antiarrhythmic drug Qualifying arrhythmia due acute reversible illness , acute myocardial infarction , and/or cardiac thoracic surgery within one month prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>